Gestational Trophoblastic Neoplasia | ||
| The Egyptian Journal of Hospital Medicine | ||
| Article 28, Volume 74, Issue 4, January 2019, Pages 934-941 PDF (322.44 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/ejhm.2019.25562 | ||
| Authors | ||
| Mahmoud Ibrahim M. Shahin* ; Wael Helmy El Sheshtawy; Mohsen Salah El-Din Zikri | ||
| Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Al-Azhar University | ||
| Abstract | ||
| Background: gestational trophoblastic neoplasia forms a wide variety of rare conditions arising from abnormal proliferation of the trophoblastic cells in the placental microvilli. They consist of vesicular mole “partial and complete”, invasive mole, placental site trophoblastic tumor (PSTT), epithelioid trophoblastic tumor (ETT) and choriocarcinoma. They can be classified into premalignant forms which include vesicular mole and malignant forms which include the rest. Aim of the Work: this study aimed tostudy the epidemiological and clinical data, as well as treatment regimes and their outcome included response and related toxicity among patients with gestational trophoblastic neoplasia treated in this study.Patients and Methods: in this retrospective study, medical records of all patients with GTN presented to Oncology Department, Al-Hussein University Hospital in the period from January 2007 to June 2017 was retrieved from the archives and medical data was reviewed and analyzed. Results: median age of patient was 37.5 (Range 20-55), molar pregnancy was the most common pathological type (40%), followed by invasive mole (31.4%), while choriocarcinoma was diagnosed in 25.7% and only 2.9% of patients had placental site trophoblastic disease. According to FIGO score; 26 patients (74.3%) showed low risk and 9 patients (25.7%) showed high risk. In low risk patients, 30.8% of patients were kept under follow up while, (69.2%) received chemotherapy, 61.1% of them achieved complete remission on methotrexate as first line chemotherapy, while the rest 38.9% achieved complete response on EMA-CO or dactinomycin as 2nd line chemotherapy. Methotrexate wasn’t effective in high risk patients, while EMA-CO had much better response achieving (66.7%) complete response rate, with 2 cases of early death in those patients. Conclusion: this retrospective study represented a single center experience and had relatively small number of cases. A large multicenter prospective trial is recommended. | ||
| Keywords | ||
| trophoblastic; neoplasia; microvilli; epithelioid trophoblastic | ||
|
Statistics Article View: 256 PDF Download: 495 |
||
